Foscavir® (Foscarnet sodium)

Foscavir® is licensed for the treatment of:

Cytomegalovirus (CMV) retinitis in HIV patients
Acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients

In Australia, Belgium, France, Germany, Hungary, Israel, Italy, Japan, Luxembourg, the Netherlands, New Zealand, Singapore, Spain, Switzerland, USA and the UK.

In Japan, Foscavir® is also indicated for the treatment of CMV in hematopoietic stem cell transplant patients.

Clinigen is committed to maintaining the supply of Foscavir® and supporting the product in each and every market.

Click here for Foscavir® enquiries

 

More information

Foscavir® Summary of Product Characteristics (SmPC)
Click here

Foscavir® Patient Information Leaflet (PIL)
Click here

If you require the SmPC in a different language, please contact our
customer services team